Immunoadsorption vs. Plasmapheresis in the Escalation Therapy of Relapse in Multiple Sclerosis
What it found
A paper reports the results; we have not read it yet. See Papers below.
What was tested
Treatment tested
- Immunoadsorption
Compared with
- Plasmapheresis
What it measured
Main measures
Multiple Sclerosis Functional Composite (MSFC)
4 weeks
Disability progression
Other measures (11)
Expanded Disability Status Scale (EDSS)
2 and 4 weeks
Disability progressionEuroQol (EQ5D-5L)
2 and 4 weeks
Quality of life (reported by participants)Response Rate
4 weeks
Disability progressionVision
4 weeks
Disability progressionVisionVisually Evoked Potentials (VEP; P100 latency)
4 weeks
Myelin repairSomatosensory Evoked Potentials (SEP; Medianus and Tibialis; N20-, P40-latency)
4 weeks
Myelin repairThickness of Retinal Nerve Fiber Layer (RNFL) in Optical Coherence Tomography (OCT)
4 weeks
Retina scans (OCT)Verbaler Lern- und Merkfähigkeitstest (VLMT) score
4 weeks
MSFC
2 weeks
Disability progressionThickness of Ganglion Cell Layer (GCL) in OCT
4 weeks
Retina scans (OCT)
Who could take part
Early (CIS/RIS) · 12 to 80
Inclusion Criteria: * relapse of Multiple Sclerosis or Clinically Isolated Syndrome (without complete remission after high dose steroid therapy) * informed consent * age ≥ 12 years old Exclusion Criteria: * clinical or laboratory signs of infection * intake of Angiotensin Converting Enzyme Inhibitor within 1 week prior to first treatment
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
This observational study investigates the efficacy and safety of immunoadsorption versus plasmapheresis in 60 patients with relapse in Multiple Sclerosis and Clinically isolated syndrome who do not fully recover after a high doses of intravenous corticosteroids.
Papers
Results
Serum neurofilament light chain and glial fibrillary acidic protein for predicting response to apheresis in steroid-refractory multiple sclerosis relapses.Eur J Neurol · 2024
Results
Dorst J, Fangerau T, Taranu D, Eichele P, Dreyhaupt J, Michels S, Schuster J, Ludolph AC, Senel M, Tumani H. Safety and efficacy of immunoadsorption versus plasma exchange in steroid-refractory relapse of multiple sclerosis and clinically isolated syndrome: A randomised, parallel-group, controlled trial. EClinicalMedicine. 2019 Nov 14;16:98-106. doi: 10.1016/j.eclinm.2019.10.017. eCollection 2019
Loading reviews and guidelines…
History
Started
Feb 2016
Main results due
Jan 2019
Finished
Jan 2019
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error